Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
John McCann, MD
D’Amour Center for Cancer Care
3350 Main Street
Springfield MA 01199
Franklin Medical Center
64 High Street
The purpose of this study is to compare overall survival for patients with stage III or stage IV melanoma who receive ipilimumab plus bevacizumab versus ipilimumab alone.
Patients with unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.